Viridian Therapeutics (VRDN) legal chief sells 14,212 shares
Rhea-AI Filing Summary
Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026. She exercised options to acquire 10,000 shares of common stock at $14.41 per share, then sold a total of 14,212 shares of common stock at $24.50 per share in open-market or private transactions, including 718 shares previously acquired under the company’s Employee Stock Purchase Plan. Following the option exercise, 114,072 option shares remain outstanding under the reported grant, which was issued on March 3, 2025 and vests in 48 equal monthly installments through March 3, 2029, with an expiration date of March 3, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Tousignant Jennifer
Role
Chief Legal Officer
Sold
14,212 shs ($348K)
Approx. gross sale proceeds
$348K
Approx. exercise cost
$144K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 10,000 | $0.00 | $0.00 |
| Sale | Common Stock F1 | 4,212 | $24.50 | $103K |
| Exercise | Common Stock | 10,000 | $14.41 | $144K |
| Sale | Common Stock | 10,000 | $24.50 | $245K |
Holdings After Transaction:
Stock Option (Right to Buy) — 114,072 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).
- F2. The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.
Key Figures
Option shares exercised: 10,000 shares
Exercise price: $14.41 per share
Shares sold: 14,212 shares
+5 more
8 metrics
Option shares exercised
10,000 shares
Stock option exercise on 2026-08-19
Exercise price
$14.41 per share
Exercise or conversion of derivative security
Shares sold
14,212 shares
Common stock sales on 2026-08-19
Sale price
$24.50 per share
Sale in open market or private transaction
Option shares remaining
114,072 shares
Derivative securities beneficially owned following transaction
ESPP shares included in sale
718 shares
Previously acquired under Employee Stock Purchase Plan
Option vesting period
48 equal monthly installments
Vesting following March 3, 2025 grant date
Option expiration date
March 3, 2035
Expiration of reported stock option
Key Terms
Stock Option (Right to Buy), Employee Stock Purchase Plan, Rule 16b-3(c)
3 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Employee Stock Purchase Plan financial
"acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(c) regulatory
"in a transaction that was exempt under Rule 16b-3(c)"
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
FAQ
What insider transactions did VRDN’s Chief Legal Officer report on this Form 4?
Jennifer Tousignant exercised stock options for 10,000 shares of Viridian Therapeutics, Inc. common stock at $14.41 per share and sold a total of 14,212 shares at $24.50 per share in open-market or private transactions on August 19, 2026.
What stock options did the VRDN insider exercise in this filing?
The reporting person exercised a stock option covering 10,000 shares of Viridian Therapeutics, Inc. common stock at an exercise price of $14.41 per share, described as an exercise or conversion of a derivative security.
What are the vesting and expiration terms of the VRDN stock option in this Form 4?
The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the grant date, subject to continued service. The option has an expiration date of March 3, 2035.
AI-generated analysis. How Rhea-AI works. Not financial advice.
